Last reviewed · How we verify
BAT7104 injection
At a glance
| Generic name | BAT7104 injection |
|---|---|
| Also known as | Recombinant anti-PD-L1/CD47 bispecific antibody injection |
| Sponsor | Bio-Thera Solutions |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BAT7104 Injection in Patients With Advanced Malignant Tumors. (PHASE1)
- BAT7104 in Patients With Advanced Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT7104 injection CI brief — competitive landscape report
- BAT7104 injection updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI